UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

Journal of clinical oncology, 2022-08, Vol.40 (23), p.2609-2611

2022

Link zum Volltext

Verfügbarkeit prüfen

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

PloS one, 2017-08, Vol.12 (8), p.e0182665-e0182665

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2872-2878

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2018-01, Vol.24 (2), p.334-340

2018

Link zum Volltext

Verfügbarkeit prüfen

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

Cell reports (Cambridge), 2020-12, Vol.33 (9), p.108444-108444, Article 108444

2020

Link zum Volltext

Verfügbarkeit prüfen

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285

2019

Link zum Volltext

Verfügbarkeit prüfen

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Nature (London), 2021-11, Vol.599 (7886), p.679-683

2021

Link zum Volltext

Verfügbarkeit prüfen

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3546-3555

2019

Link zum Volltext

Verfügbarkeit prüfen

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2021-04, Vol.27 (8), p.2209-2215

2021

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Hematology/oncology clinics of North America, 2017-02, Vol.31 (1), p.101-111

2017

Link zum Volltext

Verfügbarkeit prüfen

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Cancer, 2018-06, Vol.124 (11), p.2272-2275

2018

Link zum Volltext

Verfügbarkeit prüfen

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade

Cancer discovery, 2021-01, Vol.11 (1), p.59-67

2021

Link zum Volltext

Verfügbarkeit prüfen

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Cancer research (Chicago, Ill.), 2022-11, Vol.82 (21), p.4058-4078

2022

Link zum Volltext

Verfügbarkeit prüfen

Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

Cancer, 2018-01, Vol.124 (1), p.105-109

2018

Link zum Volltext

Verfügbarkeit prüfen

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

Current Oncology Reports, 2017-04, Vol.19 (4), p.24-24, Article 24

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2023-11, Vol.28 (11), p.978-985

2023

Link zum Volltext

Verfügbarkeit prüfen

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Clinical cancer research, 2021-05, Vol.27 (9), p.2604-2612

2021

Link zum Volltext

Verfügbarkeit prüfen

The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers

OncoTargets and therapy, 2017-01, Vol.10, p.1983-1992

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non-Small Cell Lung Cancer

JCO precision oncology, 2023-06, Vol.7, p.e2300030

2023

Link zum Volltext

Verfügbarkeit prüfen

Acquired Resistance to KRAS G12C Inhibition in Cancer

The New England journal of medicine, 2021-06, Vol.384 (25), p.2382-2393

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(79)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(35)
Humans
(29)
Oncology
(27)
Mutation
(18)
Lung Neoplasms - Drug Therapy
(14)
Lung Neoplasms - Genetics
(14)
Female
(13)
Lung Cancer
(12)
Male
(12)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(11)
Proto-Oncogene Proteins P21 - Genetics
(11)
Carcinoma, Non-Small-Cell Lung - Genetics
(10)
Cancer
(9)
Patients
(9)
Aged
(8)
Middle Aged
(8)
Adult
(7)
Treatment Outcome
(7)
Aged, 80 And Over
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer

Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non-Small Cell Lung Cancer

Acquired Resistance to KRAS G12C Inhibition in Cancer

Suchergebnisse filtern